Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

A device in clinical development appears to be far safer and more effective than the TAVI devices currently being used ...

"Aortic stenosis is deadly when not treated in a timely manner, yet its under-treatment is a widespread problem that ... if a ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

Global announces a significant milestone in our mission to restore heart valve patients to healthy function. Our ...